OpenAI published a health policy blueprint on Wednesday, staking its claim in the debate over artificial intelligence’s role in medicine. The document outlines regulatory priorities and safety standards for deploying models in clinical settings.
The move comes as tech giants accelerate efforts to embed AI into healthcare—from diagnostic tools to administrative workflows. OpenAI’s wishlist aims to shape federal guidelines before they solidify, signaling a proactive lobbying effort.
Meanwhile, Dexcom introduced updates to its continuous glucose monitors, including improved accuracy and a smaller form factor. The announcements target both Type 1 and Type 2 diabetes patients seeking less intrusive monitoring.
Yet pushback is mounting against whole-body MRI scans marketed to healthy individuals. Critics argue the screenings trigger unnecessary anxiety, follow-up procedures, and costs without proven benefits, pitting preventive hype against evidence-based caution.
“This creates a cascade of low-value care,” one radiologist noted in the report. The tension underscores the broader battle between innovation and overdiagnosis in health tech.